Published in J Natl Cancer Inst on November 27, 2007
Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA (2008) 10.92
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Predicting risk of dementia in older adults: The late-life dementia risk index. Neurology (2009) 2.92
Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol (2008) 2.56
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35
Patterns of breast magnetic resonance imaging use in community practice. JAMA Intern Med (2014) 2.08
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol (2011) 2.00
Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst (2011) 1.94
Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst (2014) 1.51
Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst (2010) 1.51
Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst (2011) 1.51
Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med (2011) 1.49
Validation of a breast cancer risk prediction model developed for Black women. J Natl Cancer Inst (2013) 1.46
Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer (2010) 1.29
Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res (2012) 1.24
Belief in numbers: When and why women disbelieve tailored breast cancer risk statistics. Patient Educ Couns (2013) 1.20
Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med (2013) 1.11
Updating risk prediction tools: a case study in prostate cancer. Biom J (2011) 1.08
Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol (2010) 1.05
Korean risk assessment model for breast cancer risk prediction. PLoS One (2013) 0.98
Breast cancer risk assessments comparing Gail and CARE models in African-American women. Breast J (2009) 0.95
Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res (2013) 0.94
Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press) (2014) 0.93
National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities. Clin Trials (2013) 0.91
Why are Tailored Messages More Effective? A Multiple Mediation Analysis of a Breast Cancer Screening Intervention. J Commun (2012) 0.89
Benign breast disease and the risk of subsequent breast cancer in African American women. Cancer Prev Res (Phila) (2012) 0.89
Predicting dementia: role of dementia risk indices. Future Neurol (2009) 0.88
Five-year and lifetime risk of breast cancer among U.S. subpopulations: implications for magnetic resonance imaging screening. Cancer Epidemiol Biomarkers Prev (2010) 0.88
Breast cancer risk assessment in 64,659 women at a single high-volume mammography clinic. Acad Radiol (2011) 0.87
Preliminary evaluation of the publicly available Laboratory for Breast Radiodensity Assessment (LIBRA) software tool: comparison of fully automated area and volumetric density measures in a case-control study with digital mammography. Breast Cancer Res (2015) 0.87
Twenty-five years of breast cancer risk models and their applications. J Natl Cancer Inst (2015) 0.86
Perceived versus objective breast cancer risk in diverse women. J Womens Health (Larchmt) (2013) 0.86
Correlation of ductal lavage cytology with ductoscopy-directed duct excision histology in women at high risk for developing breast cancer: a prospective, single-institution trial. Ann Surg Oncol (2011) 0.84
Chemoprevention for Breast Cancer. Ann Surg Oncol (2015) 0.83
Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk. J Natl Cancer Inst (2015) 0.82
Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention. Curr Breast Cancer Rep (2012) 0.82
Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. Future Neurol (2010) 0.81
Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast J (2015) 0.81
My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR). Med Decis Making (2015) 0.80
An exercise trial targeting African-American women with metabolic syndrome and at high risk for breast cancer: Rationale, design, and methods. Contemp Clin Trials (2015) 0.80
Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. Cancer (2015) 0.80
Breast density influences tumor subtypes and tumor aggressiveness. J Natl Cancer Inst (2011) 0.79
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR). Cancer Prev Res (Phila) (2012) 0.79
Impact of correlation on predictive ability of biomarkers. Stat Med (2013) 0.79
Technology- and Phone-Based Weight Loss Intervention: Pilot RCT in Women at Elevated Breast Cancer Risk. Am J Prev Med (2016) 0.78
Assessing risk of breast cancer in an ethnically South-East Asia population (results of a multiple ethnic groups study). BMC Cancer (2012) 0.78
Mammographic breast density as a risk factor for breast cancer: awareness in a recently screened clinical sample. Womens Health Issues (2014) 0.78
Individual breast cancer risk assessment in underserved populations: integrating empirical bioethics and health disparities research. J Health Care Poor Underserved (2012) 0.77
Assessing the goodness of fit of personal risk models. Stat Med (2014) 0.77
Mammographic Breast Density and Common Genetic Variants in Breast Cancer Risk Prediction. PLoS One (2015) 0.77
The changes in female physical and childbearing characteristics in China and potential association with risk of breast cancer. BMC Public Health (2012) 0.77
Traditional dietary pattern of South America is linked to breast cancer: an ongoing case-control study in Argentina. Eur J Nutr (2013) 0.77
Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women. Breast Cancer Res Treat (2013) 0.76
Prospective approach to breast cancer risk prediction in African American women: the black women's health study model. J Clin Oncol (2015) 0.76
Breast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot Study. J Oncol Pract (2015) 0.75
Lifetime and 5 years risk of breast cancer and attributable risk factor according to Gail model in Iranian women. J Pharm Bioallied Sci (2015) 0.75
Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Facilitating informed decisions about breast cancer screening: development and evaluation of a web-based decision aid for women in their 40s. BMC Med Inform Decis Mak (2017) 0.75
Randomized trial of a phone- and web-based weight loss program for women at elevated breast cancer risk: the HELP study. J Behav Med (2016) 0.75
SNPs and breast cancer risk prediction for African American and Hispanic women. Breast Cancer Res Treat (2015) 0.75
Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling. Oncotarget (2016) 0.75
MRI screening for breast cancer in women at high risk; is the Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer? J Med Radiat Sci (2015) 0.75
Predictors of Non-Adherence to Breast Cancer Screening among Hospitalized Women. PLoS One (2015) 0.75
Update in women's health. J Gen Intern Med (2009) 0.75
Predictors of preoperative MRI for breast cancer: differences by data source. J Comp Eff Res (2015) 0.75
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer (2009) 0.75
JNCI and cancer prevention. J Natl Cancer Inst (2015) 0.75
Re: Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2008) 0.75
Physician and Patient Barriers to Breast Cancer Preventive Therapy. Curr Breast Cancer Rep (2016) 0.75
Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. J Natl Cancer Inst (2016) 0.75
Risk assessment model for invasive breast cancer in Hong Kong women. Medicine (Baltimore) (2016) 0.75
Prevalence of chemopreventive agent use among hospitalised women at high risk for breast cancer: a cross-sectional study. BMJ Open (2016) 0.75
Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ. Cancer Prev Res (Phila) (2017) 0.75
Development of a cancer risk prediction tool for use in the UK Primary Care and community settings. Cancer Prev Res (Phila) (2017) 0.75
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer (2017) 0.75
Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk. Breast Cancer Res Treat (2017) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med (2003) 6.47
Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect (2004) 6.43
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol (2007) 6.11
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol (2007) 5.39
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
Effect of population-based screening on breast cancer mortality. Lancet (2011) 5.06
Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst (2006) 4.95
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol (2010) 4.81
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control (2008) 4.56
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med (2013) 4.36
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10
Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol (2002) 3.99
Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol (2007) 3.86
Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst (2003) 3.83
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol (2006) 3.79
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol (2010) 3.79
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol (2012) 3.65
Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol (2010) 3.64
Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res (2006) 3.62
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst (2011) 3.54
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst (2006) 3.36
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer (2003) 3.25
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst (2008) 3.17
Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev (2003) 3.11
Influence of individual and combined health behaviors on total and cause-specific mortality in men and women: the United Kingdom health and lifestyle survey. Arch Intern Med (2010) 3.08
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
The landscape of recombination in African Americans. Nature (2011) 3.06
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res (2006) 3.06
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol (2003) 3.05
Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA (2003) 3.04
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity. Matern Child Health J (2007) 2.89
Physical activity levels among breast cancer survivors. Med Sci Sports Exerc (2004) 2.88
Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol (2008) 2.85
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res (2004) 2.80
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Long-term exposure to constituents of fine particulate air pollution and mortality: results from the California Teachers Study. Environ Health Perspect (2009) 2.72
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol (2002) 2.67
Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol (2003) 2.65
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst (2004) 2.62
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Barriers to racial/ethnic minority application and competition for NIH research funding. J Natl Med Assoc (2005) 2.60
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59
The effect of an anatomically classified procedure on antiemetic administration in the postanesthesia care unit. Anesth Analg (2009) 2.59
Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol (2008) 2.56
Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer (2008) 2.56
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol (2008) 2.55